Avacta's JV AffyXell receives $7.3 million in series A financing
Biotherapeutics and reagents company Avacta said AffyXell Therapeutics, its joint venture with Daewoong Pharmaceutical, had closed a series A venture capital investment of $7.3 million...
Mon, 01/02/2021 - 09:33